Optimising gentamicin therapy in paediatric oncology patients

2018 ◽  
Author(s):  
Carolina Consuelo Llanos Paez
Keyword(s):  
Paediatric Oncology ◽  
Oncology Patients ◽  
Gentamicin Therapy

Imaging Findings of Paediatric Oncology Patients Presenting with Acute Neurological Symptoms

2003 ◽  
Vol 58 (8) ◽  
pp. 589-603 ◽  
Author(s):  
W.C.W Chu ◽  
V Lee ◽  
R.G Howard ◽  
D.J Roebuck ◽  
K.W Chik ◽  
...  
Keyword(s):  
Paediatric Oncology ◽  
Neurological Symptoms ◽  
Imaging Findings ◽  
Oncology Patients

Surgical strategies in the management of ecthyma gangrenosum in paediatric oncology patients

2008 ◽  
Vol 24 (7) ◽  
pp. 793-797 ◽  
Author(s):  
B. A. Khalil ◽  
C. T. Baillie ◽  
S. E. Kenny ◽  
G. L. Lamont ◽  
R. R. Turnock ◽  
...  
Keyword(s):  
Paediatric Oncology ◽  
Oncology Patients ◽  
Surgical Strategies ◽  
Ecthyma Gangrenosum

scholarly journals High incidence of cisplatin-induced ototoxicity in paediatric patients in the Western Cape, South Africa

2018 ◽  
Vol 2 ◽  
Author(s):  
Mukovhe Phanguphangu ◽  
Lebogang Ramma
Keyword(s):  
Hearing Loss ◽  
Otoacoustic Emissions ◽  
Negative Impact ◽  
Paediatric Oncology ◽  
Cancer Drug ◽  
Oncology Patients ◽  
Profound Hearing Loss ◽  
Distortion Product ◽  
High Incidence

Background: Fourteen million new cancer cases are reported annually, and up to 10% of those involve children below 15 years. Cisplatin, a commonly used anti-cancer drug for its high success rate, is associated with ototoxicity. Cisplatin-induced ototoxicity is characterised by permanent bilateral severe-to-profound hearing loss. Hearing loss, when occurring during childhood, can impact negatively communication development, scholastic performance and quality of life.Aim: To determine the incidence of cisplatin-induced ototoxicity in paediatric oncology.Setting: A retrospective records review of paediatric oncology patients who underwent cisplatin-based chemotherapy and had ototoxicity monitoring from January 2015 to December 2017 at a children’s hospital.Method: Data collected included demographic, cisplatin treatment and audiometric information. The data were analysed using descriptive and inferential statistics.Results: A total of 49 records meeting the inclusion criteria were reviewed. Ototoxic hearing loss was found in 39 (80%) of the patients whose records were reviewed and the majority (56%) presented with a bilateral moderate-to-severe sensorineural hearing loss. Distortion product otoacoustic emissions were absent in 32 (67%) patients. Cumulative dose (> 200 mg/m2) was associated with higher incidences of ototoxicity (odds ratio [OR]: 1.81; 95% confidence interval [CI]: 0.67–17.34; p = 0.044). Younger patients (< 10 years) had higher odds of developing ototoxicity, but this was not statistically significant (OR: 4.00; 95% CI: 0.82–19.46; p = 0.085).Conclusion: This study found a high incidence of cisplatin-induced ototoxicity in paediatric oncology patients. This is concerning because hearing loss during this age can have long-term negative impact on a child’s development and overall quality of life. Early identification of ototoxicity-induced hearing loss and appropriate intervention are highly recommended in this patient group.

Sign in / Sign up

Export Citation Format

Share Document